In all 20 healthy adults who received an experimental vaccine in a Phase 1 clinical trial to prevent Ebola virus disease, the vaccine was well-tolerated and produced immune system responses. The clinical trial was conducted by researchers from the National Institutes of Health. The candidate vaccine, which was co-developed by the NIH's National Institute of Allergy and Infectious Diseases (NIAID) and GlaxoSmithKline (GSK), was tested at the NIH Clinical Center/a ...
via Medindia Health News
More READ 
Lake forest health and fitness http://ift.tt/1yfOilg
No comments:
Post a Comment